Aelis Farma Secures Funding to Advance Groundbreaking Brain Disease Treatments

Aelis Farma, a pioneering clinical-stage biopharmaceutical company based in Bordeaux, has announced a significant funding milestone aimed at propelling its innovative therapies for brain diseases. In its latest round, Aelis Farma successfully raised **$10 million**, a strategic investment that will accelerate the development of their groundbreaking Signaling Specific inhibitors of the CB1 receptor (CB1-SSi) of the endocannabinoid system. These novel drug candidates uniquely mimic a newly discovered natural defense mechanism of the brain, offering potential treatments for various neurological disorders that currently lack effective therapies. Aelis Farma's lead candidates, AEF0117 and AEF0217, are currently in advanced clinical trials; AEF0117 has shown promising results in treating disorders associated with excessive cannabis use, progressing to a phase 2b clinical trial following favorable phase 2a outcomes. Meanwhile, AEF0217 is being evaluated for its efficacy in addressing cognitive deficits, particularly those linked to Down syndrome, with initial clinical trials yielding no major adverse effects to date. The new funding will not only facilitate these ongoing trials but also support the expansion of Aelis Farma's pipeline, leveraging their proprietary platform to explore additional CB1-SSi candidates for various brain pathologies. With a talented team of 24 professionals and strong backing from regional investment partners including Nouvelle-Aquitaine Region and Bpifrance, Aelis Farma is poised to make a profound impact on the landscape of brain health treatment, addressing high unmet medical needs and redefining pharmacological approaches in the process.